AEROCRINE REINFORCES MANAGEMENT TEAM


AEROCRINE REINFORCES MANAGEMENT TEAM

SOLNA, Stockholm - 24th of August 2007 - In August Kjell Alving, Professor at
the Karolinska Institute, joined Aerocrine's management team responsible for
scientific and medical affairs.

Kjell Alving is one of the pioneers within the field of exhaled nitric oxide
(NO) research and its clinical applications and has an extensive network within
the international asthma community. 
In the early 1990s, Kjell was one of the researchers at the Karolinska Institute
who discovered that exhaled NO was connected to lung inflammation. He found that
people with asthma have higher levels of exhaled NO than healthy individuals.
These discoveries led to the establishment of Aerocrine, of which Kjell is one
of the founders. In 1990 he received a PhD in pharmacology at the Karolinska
Institute. Since then, he has led a research group that, among other things, has
focused on documenting the clinical use of exhaled NO in the treatment of
asthma. 
Kjell will continue to work part-time as a professor at the Department of
Women's and Children's Health at Uppsala University, but will spend most of his
time at Aerocrine. 
 
“We are very pleased and proud that Kjell will now use his well-founded
expertise and experience to support Aerocrine's mission to expand the clinical
use of exhaled NO for asthma care," say Paul de Potocki, CEO of Aerocrine.
"Kjell's profound knowledge regarding exhaled NO and its role in asthma
management will reinforce the likelihood of our success." 

For additional information, contact: 
Paul de Potocki, CEO, tel: +46 8 629 07 82

About Aerocrine 
Aerocrine AB (publ.) is a clinically based medical technology corporation
dedicated to improved asthma management and care. The company is marketing NIOX®
Flex on a worldwide basis and is also marketing NIOX MINO®, representing a new
generation of hand-held devices, in Europe. Both products are tailored for
rapid, non-invasive control of the inflammatory status in the airways and may
play a critical role for a more efficient diagnosis, treatment and monitoring of
asthma patients. Aerocrine is located in Sweden with wholly owned subsidiaries
in the US, UK and Germany.

Attachments